The Apoptotic Effect of the Hexane Extract of Rheum undulatum L. in Oral Cancer Cells through the Down-regulation of Specificity Protein 1 and Survivin by Choi, Eun-Sun et al.
19
The Apoptotic Effect of the Hexane Extract of Rheum undulatum L. 
in Oral Cancer Cells through the Down-regulation of
Specificity Protein 1 and Survivin
Eun-Sun Choi
1, Sung-Dae Cho
1, Jae-Gyu Jeon
2 and Nam-Pyo Cho
1*
1Department of Oral Pathology, School of Dentistry and Institute of Oral Bioscience, Brain Korea 21
Chonbuk National University, Jeonju, Republic of Korea
2Department of Preventive Dentistry, School of Dentistry and Institute of Oral Bioscience, Brain Korea 21,
Chonbuk National University, Jeonju, Republic of Korea
The hexane extract of Rheum undulatum L. (HERL) has been shown to have anti-cancer activity in several
cancers in vivo and in vitro. However, the anti-cancer activity of HERL and its molecular mechanism in
human oral cancer cells has not been explored. Thus, the aim of this study was to elucidate the growth-
inhibitory and apoptosis-inducing effects of HERL in HN22 and SCC15 oral cancer cell lines. This study
shows that HERL inhibits oral cancer growth, decreases cell viability, and causes apoptotic cell death in
HN22 and SCC15 cells, as characterized by morphological changes, nuclear condensation and
fragmentation, the cleavage of PARP and the accumulation of cells in the sub-G1 phase. The treatment of
oral cancer cells with HERL also resulted in decreased expression of specificity protein (Sp1) and its
downstream protein, survivin. Therefore, our results suggest that the regulation of Sp1 and survivin plays
a critical role in HERL-induced apoptosis in human oral cancer cells.
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Oral and pharyngeal cancer is the sixth most common
cancer world-wide and two-thirds of these cases occur in
developing countries (Parkin et al, 2005). Despite advances
in cancer diagnosis and treatment, there has been little
improvement in the 5-year survival rate of oral cancer patients
in the last few decades. Because of this, various approaches
have been used in the clinical treatment of oral cancer patients
in the last three decades, from non-targeted chemotherapy
to highly targeted pharmacological inhibitors and specific
monoclonal antibodies (Hamakawa et al, 2008; Scully and
Bagan, 2009). Although targeted therapies yield better
outcomes than non-targeted therapies, frequent treatment
failure suggests the need for new strategies for this disease,
including new drugs or targets.
Rheum undulatum L. (RL), a well-known traditional Chinese
medicine, has been widely used for thousands of years in
China for the treatment of many diseases (He et al, 2009).
In particular, the root of the species is widely used as a purgative
and anti-inflammatory agent in East Asia (Chang et al, 1996;
Kuo et al, 2001; Yu et al, 2008). It has been also reported
that RL is used traditionally in Korea for the treatment of
dental disease (Kim et al, 2010). Recently, it was found that
RL  contains many anthraquinones and their glycosides,
including aloe-emodin, rhein, emodin, and chrysophanol,
which are thought to be the major active components for
inhibiting tumor growth in various cancer cells (Cha et al,
2005; Huang et al, 2006; Huang et al, 2007; Dorsey and
Kao, 2007). However, there has been no study performed
to investigate the effect of RL on the growth of human oral
cancer cells.
In the present study, we examined the effect of the hexane
extract of Rheum undulatum L.  (HERL)  on the growth of
oral cancer cells and the molecular targets for HERL-induced
apoptosis. The results demonstrated that HERL induced
apoptotic cell death to inhibit the proliferation of oral cancer
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cells and the down-regulation of Sp1 and survivin mediated
the anti-cancer activity of HERL.
Materials and Methods
Reagents
The antibodies for poly(ADP-ribose) polymerase (PARP) and
survivin were obtained from BD Biosciences (San Jose, CA,
USA) and Cell Signaling Technology (Danvers, MA, USA),
respectively. Antibodies for Sp1 and actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 4’-
6-Diamidino-2-phenylindole (DAPI) and propidium iodide
(PI) were acquired from Sigma-Aldrich (St. Louis, MO, USA).
HERL was kindly supplied by professor Jeon JG (Jeonbuk
National University, Jeonju, Korea).
Cell culture and chemical treatment
The HN22 and SCC15 human oral cancer cell lines were
obtained from the School of Dentistry, Dankook University
(Cheonan, Korea). The cells were cultured in Dulbecco’s
modified essential medium (DMEM) containing 10% fetal
bovine serum (FBS) and 100 units/mL penicillin and 100
µg/mL streptomycin (WelGENE, Daegu, Korea) in a humid
atmosphere of 5% CO2. Equal numbers of cells were seeded
and allowed to attach overnight. The cells were treated with
0.1% NaCl or HERL (20, 40 or 60 µg/mL) diluted in DMEM
with 5% FBS for 48 h.
MTS assay
The effects of HERL on cell viability were estimated using
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay
Kit (Promega, Madison, WI, USA) according to the manufacturer’s
instructions. The cells were seeded in 96-well plates and
incubated with various concentrations of HERL. After the
treatment with HERL for 48 h, 30  µL of 3-(4,5-dimethylthiazol-
20yl)-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-
tetrazolium) (MTS) solution was added to each well and the
cells were incubated for 2 h at 37
oC. MTS solution was analyzed
using a microplate reader (BioTeck Instruments, Winooski,
VT, USA) at 490 and 690 nm (background).
FACS analysis for sub-G1 DNA measurement
After treatment with HERL for 48 h, the detached HN22
and SCC15 cells were collected and combined with the
adherent cells that had been released by trypsinization. The
cells were fixed in 70% ethanol overnight at −20
oC. The
cells were subsequently stained with 0.02 mg/mL PI. The data
were acquired using a FACScan flow cytometer.
DAPI staining
The number of cells with nuclear condensation and
fragmentation was measured using DAPI staining. After
treatment with HERL or 0.1% NaCl (control), the HN22 and
SCC15 cells were harvested by trypsinization. The cells were
resuspended in PBS, deposited on poly-L-lysine-coated slides,
stained with DAPI solution (2 µg/mL) and observed under
a fluorescence microscope.
Western blot analysis
After treatment with HERL, HN22 and SCC15 cells were
harvested. The protein supernatant fractions were subjected
to SDS-PAGE and then transferred to polyvinylidene difluoride
(PVDF) membranes and blocked with 5% skim milk followed
by hybridization with the indicated antibodies. After incubation
with the horseradish peroxidase (HRP)-conjugated secondary
antibody, the immunoreactive protein bands were observed
using a chemiluminescence detection kit.
Statistical analysis
Data were assessed for statistical significance using a
Student’s t-test. A value of P<0.05 compared to the vehicle
control was considered statistically significant.
Results
HERL  decreases  the  cell  viability  in  oral  cancer
cell lines
We first investigated the effect of HERL on the growth
of HN22 and SCC15 cells. HERL-treated cells were detached
from the dishes compared to 0.1% NaCl-treated cells and
these morphological changes occurred in a dose-dependent
manner (Figure 1A). We also measured the effect of HERL
on cell viability in the MTS assay. The results showed dose-
dependent decreases of cell viability in HN22 and SCC15
cells (Figure 1B). These results suggest that HERL has a growth-
inhibitory effect on HN22 and SCC15 cells.
HERL induces apoptosis in oral cancer cell lines
To examine whether HERL induced apoptosis, the number
of cells accumulated in the sub-G1 phase of the cell cycle
was counted by flow cytometric analysis. As shown in Figure
2, the sub-G1 population of HERL-treated cells accumulated
in a dose-dependent manner compared to the vehicle control.
To confirm the induction of apoptosis by HERL in HN22
and SCC15 cells, DAPI staining was performed and showed
the fragmentation and condensation of nucleus in the cells
treated with HERL (20, 40 and 60 µg/mL) for 48 h comparedRheum undulatum L. induces apoptosis of oral cancer cells 21
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to the control (Figure 3). We next determined the level of
PARP cleavage by Western blot analysis (Figure 4). After HERL
treatment for 48 h, cleaved PARP was detected in the HN22
and SCC15 cells. Thus, we clearly showed that HERL induced
apoptosis in HN22 and SCC15 cells to inhibit cell growth.
HERL  inhibited  anti-apoptotic  protein  Sp1  and
survivin in oral cancer cell lines
In previous studies, it was reported that targeting of Sp1
protein is a good treatment strategy for various cancer cells
(Lou et al, 2005; Safe and Abdelrahim, 2005; Abdelrahim
Figure 1. Morphological changes and the viability of HN22 and SCC15 cells after treatment with hexane extract of Rheum
undulatum L. (HERL). A, Photomicrographs of HN22 and SCC15 cells treated with 20, 40 and 60 µg/mL of HERL for 48 h. B, Cell
viability was determined using MTS assay. The graph was representative of three independent experiments and bar is mean±SD.
*P<0.05 compared to control group.
Figure 2. The effect of hexane extract of Rheum undulatum L. (HERL) on cell accumulation in sub-G1 phase. The sub-G1
population was measured by PI staining and flow cytometry analysis. The bar graph represents three independent experiments and
mean±SD. *P<0.05 compared to control group.22 Eun-Sun Choi et al
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et al, 2006; Papineni et al, 2009; Lu and Archer, 2010) and
Sp1 protein regulates survivin protein as the downstream
protein to induce apoptosis in cancer cells (Shin et al, 2010).
Therefore, we assessed whether HERL affects Sp1 and survivin
protein to induce apoptotic cell death in HN22 and SCC15
cells. As shown in Figure 5, HERL-treated HN22 and SCC15
cells exhibited decreased Sp1 and survivin expression in a
dose-dependent manner. These results suggest that HERL
might inhibit Sp1 and survivin protein to exert its apoptotic
activity in HN22 and SCC15 cells.
Discussion
Natural extracts from edible plants have been identified
as excellent candidates for cancer therapeutics based on safety
and efficacy (Stewart et al, 2003). Recently, Rheum undulatum
L. was screened for anti-cancer activity in vitro using human
breast, ovary, cervix and lung cancer cell lines (Kang et al,
2008). In that study, emodin showed strong cytotoxicity in
both estrogen receptor (ER)-positive and -negative breast
cancer cell lines (Kang et al, 2008). In addition, HERL was
shown to inhibit angiogenic activity in a zebrafish model (He
et al, 2009). These studies suggest that HERL has potential
benefits for the treatment of various cancers. However, the
anticancer activity of HERL against oral cancer cells has not
been well established. Therefore, we focused on the anticancer
activity of HERL in human oral cancer cells. Our first purpose
was to examine the anti-proliferative and pro-apoptotic effects
Figure 3. The effect of hexane extract of Rheum undulatum L. (HERL) on the condensation and fragmentation of nucleus in HN22
and SCC15 cells. Fluorescence microscopy images of DAPI-stained HN22 and SCC15 cells showing the appearance of apoptotic
morphology.
Figure 4. The effect of hexane extract of Rheum undulatum L. (HERL) on the cleavage of poly(ADP-ribose) polymerase (PARP) in
HN22 and SCC15 cells. HN22 and SCC15 cells were treated with 20, 40 or 60 µg/mL of HERL for 48 h, and then the protein levels
of cleaved PARP were determined by Western blot analysis. Actin was used to normalize the protein loading from each treatment.
Figure 5. The effect of hexane extract of Rheum undulatum L. (HERL) on the regulation of Sp1 and survivin protein expression.
Sp1 and survivin protein levels were analyzed by Western blot analysis.Rheum undulatum L. induces apoptosis of oral cancer cells 23
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of HERL on oral cancer cell lines and the other was to determine
its molecular mechanism in HERL-induced apoptosis. First,
we found that HERL decreased the number of viable cells
in a dose-dependent manner, showing that HERL has an
inhibitory effect on cell growth in HN22 and SCC15 cells.
We found that HERL induced the apoptosis of HN22 and
SCC15 cells as evidenced by the accumulation of sub-G1
phase cells, distinct chromatin condensation and nuclear
fragmentation of the nucleus and the cleavage of PARP protein,
a typical apoptotic marker.
Sp1 is a member of the mammalian transcription factor
family that binds to GC-rich sites containing GC-boxes.
Recently, it was reported that Sp1 protein is over-expressed
in many human tumors and cancer cell lines (Zannetti et
al, 2000; Chiefari et al, 2002; Wang et al, 2003; Hosoi et
al, 2004; Yao et al, 2004). Sp1 has also been implicated
in multiple cell processes, including apoptosis, through
activation of the FAS-ligand (Kavurma et al, 2001; Sun et
al, 2001). In addition, survivin, an inhibitor of apoptosis and
a key regulator of mitosis, is up-regulated in a variety of cancer
cells and is often associated with a worse prognosis (Sun
et al, 2001). Interestingly, several studies have shown that
survivin expression can be regulated by Sp1 protein because
it contains highly GC-rich sequences within its promoters (Li
and Altieri, 1999; Wu et al, 2005; Li et al, 2006; Shim et
al, 2010). Therefore, we examined the effects of HERL on
the expression of Sp1 and its downstream target, survivin,
as the key molecular factors in human oral cancer cells. Our
results show that HERL decreases the expression levels of
Sp1 and survivin proteins, suggesting that HERL inhibits the
growth and induces apoptosis in HN22 and SCC15 cells
through the regulation of Sp1 and survivin.
In summary, our data showed HERL exerts pro-apoptotic
and anti-proliferative effects in HN22 and SCC15 human
oral cancer cells and that Sp1 and survivin play important
signaling roles in HERL-induced apoptosis. Therefore, we
suggest that HERL is a promising anti-cancer drug candidate
for the effective treatment of oral cancer.
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